First, we model a 20% weight reduction based on clinical trial results for tirzepatide (Zepbound and Mounjaro), while ICER estimated a 13.7% weight reduction based on evidence for semaglutide
The goal is to lose fat while maintaining strength, mobility, and metabolic function
If you frequently miss doses, reassess your routine
The GLP-1 shortage which has impacted access to popular weight loss and diabetes management drugs like Wegovy and Ozempic has left many patients scrambling to find their necessary medications
At the Primary Care Center of Clear Lake, our approach involves a thorough assessment of each patients condition, considering factors such as the type of diabetes, lifestyle, and treatment goals
The data on cardiovascular and neurologic benefits are promising, but we must be cautious